Download PDF
CC BY-NC-ND 4.0 · Endosc Int Open 2022; 10(12): E1526-E1527
DOI: 10.1055/a-1965-3191
Editorial

EUS-guided treatments of pancreatic cystic neoplasms – a call for methodological improvements

Andrea Lisotti‡
1   Gastroenterology Unit, Hospital of Imola, University of Bologna, Imola, Italy.
,
Ryan Law‡
2   Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester, Minnesota, United States
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Pancreatic cystic neoplasms (PCN) affect up to 5 % of the general population, with a relative prevalence increase in recent decades, mostly due to increased life-expectancy and the improvements in the diagnostic potential and widespread availability of cross-sectional imaging [1] [2].



Publication History

Article published online:
15 December 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Refers to:

Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cystsEndosc Int Open 2022; 10(12): E1517-E1525
DOI: 10.1055/a-1949-7730

 

  • References

  • 1 Tanaka M, Fernandez-del Castillo C, Kamisawa T. et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017; 17: 738-753
    CrossrefPubMedSearch in Google Scholar
  • 2 The European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018; 67: 789-804
    Search in Google Scholar
  • 3 Lisotti A, Napoleon B, Facciorusso A. et al. Contrast-enhanced EUS for the characterization of mural nodules within pancreatic cystic neoplasms: systematic review and meta-analysis. Gastrointest Endosc 2021; 94: 881-889
    CrossrefPubMedSearch in Google Scholar
  • 4 Othman MO. et al. Early phase trial of intracystic injection of large-surface-area microparticle paclitaxel for the treatment of mucinous pancreatic cysts. Endoscopy Int Open 2022; 10: E1517-E1525
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Teoh AY, Seo DW, Brugge W. et al. Position statement on EUS-guided ablation of pancreatic cystic neoplasms from an international expert panel. Endosc Int Open 2019; 7: E1064-E1077
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Attila T, Adsay V, Faigel DO. The efficacy and safety of endoscopic ultrasound-guided ablation of pancreatic cysts with alcohol and paclitaxel: a systematic review. Eur J Gastroenterol Hepatol 2019; 31: 1-9
    CrossrefPubMedSearch in Google Scholar
  • 7 Barthet M, Giovannini M, Lesavre N. et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy 2019; 51: 836-842
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Barthet M, Giovannini M, Gasmi M. et al. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open 2021; 9: E1178-E1185
    Thieme ConnectPubMedSearch in Google Scholar